Aquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity Analysts
Aquinox Pharmaceuticals (NASDAQ:AQXP) has been given a $22.00 price target by equities researchers at Canaccord Genuity in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 108.14% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Zacks Investment Research cut Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $22.50.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.03 on Monday, hitting $10.57. The stock had a trading volume of 95,500 shares, compared to its average volume of 85,455. Aquinox Pharmaceuticals has a fifty-two week low of $10.20 and a fifty-two week high of $19.97.
WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/aquinox-pharmaceuticals-aqxp-given-a-22-00-price-target-by-canaccord-genuity-analysts.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.